Pub. Date : 2011 Nov 15
PMID : 21844014
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | RESULTS: The combination of riluzole with sorafenib exhibited enhanced antitumor activities in GRM1-expressing melanoma cells harboring either wild-type or mutated B-RAF. | Sorafenib | glutamate metabotropic receptor 1 | Homo sapiens |
| 2 | The combination of riluzole with PLX4720 showed lessened efficacy compared with the combination of riluzole and sorafenib in suppressing the growth of GRM1-expressing cells harboring the B-RAF(V600E) mutation. | Sorafenib | glutamate metabotropic receptor 1 | Homo sapiens |
| 3 | CONCLUSIONS: The combination of riluzole with sorafenib seems potent in suppressing tumor proliferation in vitro and in vivo in GRM1-expressing melanoma cells regardless of B-RAF genotype and may be a viable therapeutic clinical combination. | Sorafenib | glutamate metabotropic receptor 1 | Homo sapiens |